Recent studies have confirmed the benefit of cholesterol reduction in the secondary prevention of ischaernic heart disease! and a recent editorial has cogently summarized the reasons why.? The objective of therapy is to reduce total cholesterol values to 5·2 mrnol/L or less. The fibric acid derivative class of lipid lowering agent have been demonstrated to be useful agents for the treatment of hyperlipidaemia! and for regression of atheroma.' They are considered particularly useful when there is hyperlipidaemia associated with increased triglycerides and for their documented effect on increasing the highdensity lipoprotein fraction (HDL) as well as decreasing low-density lipoprotein (LDL).4 Such patients may be routinely monitored by following the total cholesterol. We present a case report of paradoxical reduction in HDL due to fenofibrate and illustrate the importance of lipoproteins in monitoring therapy.
ANALYTICAL METHODS
Blood samples were obtained following a 12 h overnight fast into tubes with gel separator tubes for routine investigations (including lipoproteins) or plain tubes without anticoagulants (apolipoproteins and troponin T) (Vacutainer, Becton-Dickinson, Oxford, UK). Serum was separated and stored at 4°C prior to analysis. All routine analyses were performed within 24 h. Lipoproteins and apolipoproteins were measured within 72 h.
Aspartate transaminase (AST), alanine transaminase (ALT), creatine kinase (CK), alkaline phosphatase (ALP), cholesterol (cholesterol oxidase method, within batch CV 0·7%, between batch CV 1·8% at 8·2mmol/L) and triglyceride (lipoprotein lipase/glycerol kinase method, within batch CV 0,7%, between batch CV 2·2% at Correspondence: Dr Collinson. 4'2mmol/L) were measured using an AXON analyser (Bayer, Hampshire, UK) by the manufacturers recommended methods. All enzyme measurements were made at 37°C by optimized methods.
Apolipoprotein A (apo A) and apolipoprotein B (apo B) were measured by an automated nephelometric method on a Beckmann Array (Beckmann Instruments, Buckinghamshire, UK) by the manufacturers' recommended methods. For apo A, within batch and between batch CV were 0·95% and 1·07%, respectively, at 1·43 gIL. For apo B, within batch and between batch CV were 0·31 % and 1·25%, respectively, at 0·47 gIL.
HDL cholesterol was measured by polyethyleneglycol (PEG) precipitation, within and between batch CVs were 3·9% and 5% respectively, at 1·6 mmol/L, LDL was calculated by the Friedwald equation when the triglycerides were less than 5 mmol/L, Troponin Twas measured by ELISA using the ES 300 automated immunoassay system (Boehringer Mannheim UK, East Sussex, UK).
CASE HISTORY
A 53-year-old man presented to the hospital with chest pain, subsequently confirmed by electrocardiogram (ECG) changes and serial creatine kinase measurement to be myocardial infarction by World Health Organization criteria (peak CK of 2445, upper reference limit 200, plus development of new Q waves on serial electrocardiography). He was initially treated with eminase (APSAC). Subsequent echocardiography showed the presence of an apical dyskinetic segment and an apical thrombus so he was anticoagulated with warfarin. He was discharged after an uneventful recovery on warfarin 8 mg and atenolol 50 mg daily. Warfarin was discontinued and he was commenced on aspirin 75 mg and changed from atenolol to bisoprolol 5 mg daily. He was commenced on enalapril 2'5mg increasing to 5 mg. Radionuclide angiography confirmed an apical infarction with reduced ejection fraction. Initial investigation showed a total cholesterol of 6'4mmoI/L, triglycerides 5·3 mmol/L with no secondary causes of hyperlipidaemia. Serum AST, ALT and ALP were within the reference intervals. Conservative management by dietary intervention failed to reduce LDL to less than 3·4mmol/L. As he had primary combined hyperlipidaemia, he was commenced on fenofibrate 100mg twice daily, increasing to 200mg twice daily after 1 month. There was failure to reach target LDL after 58 weeks and he was transferred to ciprofibrate 100mg.
There was an initial fall in serum HDL on fenofibrate, and serum HDL was undetectable after commencement on ciprofibrate therapy (Table 1) . He was then reviewed and apolipoproteins measured. Clinically he felt tired and was suffering from a dry mouth. Serum apo A was not detectable and serum apo B concentration was 2·2 giL. The patient had evidence of deranged liver function with serum AL T 68 IUI L (upper reference limit 40), and serum AST 58 lUlL (upper reference limit 40). Serum creatine kinase was elevated at 488 lUlL (upper reference limit 200) but cardiac muscle damage was excluded as cardiac troponin T was not detected.
Ciprofibrate was discontinued and the patient monitored weekly. There was return of serum Ann Clin Biochem 1996: 33 HDL concentration to pretreatment values over the course of the next 4 weeks with increase in apolipoprotein A concentration to within the reference interval (see Table 1 ). Serum CK returned to within the reference interval within 3 weeks. Clinically, the patient felt less tired and the dry mouth from which he had been suffering improved. Liver function tests returned to within the reference interval by 56 days from cessation of ciprofibrate.
DISCUSSION
The changes in serum total cholesterol concentration, a slight reduction on treatment with fenofibrate then ciprofibrate and the subsequent rise after cessation of treatment are almost entirely due to changes in serum HDL concentration. Serum HDL concentration decreased initially on fenofibrate, and became undetectable after commencement on ciprofibrate therapy. If only total cholesterol had been measured, this would not have been detected (see Table 1 ). There are no other reports of HDL reduction due to fenofibrate. There have been two case reports 5 • 6 which show that ciprofibrate can result in marked decrease in serum HDL concentration. We have seen three other patients, in addition to this case, where there has been a reduction in serum HDL concentration due to ciprofibrate therapy. In addition, there is one case report of reduction in serum HDL in a patient receiving bezafibrate.? We suggest that this effect may not be particular to fenofibrate and ciprofibrate, but may be a class effect of the fibrate group of drugs. The fibrates as a rule raise serum HDL. The decrease in serum HDL we observed is extremely rare.
This case also shows the effect of ciprofibrate on aminotransferases and skeletal muscle as reported previously.! The symptomatic improvement is similar to that reported by McLeod et al. 6 The time course is compatible with the reported half life of the drug of 80 h. The mechanism for reduction in serum HDL must remain speculative, but the prompt resolution of the problem on cessation of therapy suggests that there may be an effect on production of apo A in these patients.
We would therefore recommend that patients who receive fibrate therapy have regular measurements of lipoproteins rather than total cholesterol alone to monitor response to therapy.
